Study Title
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Purpose
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions.
For more information please visit
https://clinicaltrials.gov/study/NCT04759664
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at 318-212-8671.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
** WK New Format
IRB Number:
Trial Type:
Device
Sponsor:
** WK New Format
Contact Information: